Recruiting

CHANTIX

Sponsor:

Newark Beth Israel Medical Center

Code:

NCT01170338

Conditions

Smoking

Acute Coronary Syndrome

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Varenicline 100 mg by mouth twice daily

control

Study Details

Brief summary:

Assess the role of a nicotine antagonist in helping patients presenting to hospital with acute coronary syndrome to stop smoking.

Conditions

Smoking

Acute Coronary Syndrome

Study ID

NCT01170338

Start date

Jan, 2008

Status verified date

Jul, 2010

Primary completion date

Jul, 2011

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • active smokers presenting to hospital with an acute coronary syndrome

Exclusion Criteria:

  • patients with an acute coronary syndrome who are not active smokers

Study Design

Enrollment

100 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: active Chantix

active drug to help smoking cessation

placebo comparator: sugar pill

Interventions

Varenicline 100 mg by mouth twice daily

this is an active drug to help smoking cessation

control

this is the placebo that will help us maintain a blinded study

Primary outcome measure

  • nicotine levels [ Time Frame: 1 month ]

Central Contacts and Locations

Locations

Newark Beth Israel Medical Center

Recruiting

Newark, New Jersey, United States, 07112

Contacts

Marc Cohen, MD

973-926-7852marcohen@sbhcs.com

Principal Investigator:

Marc Cohen, MD

More Information

Sponsor

Newark Beth Israel Medical Center

Last update posted

Jul 27, 2010

Last verified

Jul, 2010

Keywords

  • smoking
  • tobacco abuse

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Newark Beth Israel Medical Center on 2010-07-27.